Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial
Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial
复制标题
甲磺酸伊马替尼治疗软组织和骨肉瘤：肉瘤研究联盟 (SARC) II 期试验的中期结果
DOI：
10.1200/jco.2004.22.90140.9001
复制
发表时间：
2004
影响因子：
45.3
通讯作者：
L. Baker
中科院分区：
文献类型：
--
作者：
R. Chugh;Dafydd G. Thomas;K. Wathen;P. Thall;R. Benjamin;R. Maki;B. Samuels;M. Keohan;D. Priebat;L. Baker
9001 Background: The success of imatinib (Gleevec) in gastrointestinal stromal tumor (GIST) is proof that a small oncogene targeted molecule can have significant benefit in a solid tumor. Sarcomas, other than GIST, also overexpress one or more of the tyrosine kinases inhibited by imatinib. We are performing a multi-institutional study to evaluate imatinib activity in nine different sarcoma subtypes and desmoid tumors. Methods: Patients ≥10 years old with a sarcoma subtype not curable by multidisciplinary management were eligible. Imatinib was prescribed at 300 mg BID (BSA≥1.5m2), 200 mg BID (BSA=1.0–1.49m2), or 100 mg BID (BSA<1.0m2). Responses at two and four months were collected. Rules for early termination within each disease type were based on a hierarchical Bayesian probability model accounting for correlation of the responses of the 10 disease types. Tissue specimens were analyzed by immunohistochemistry for c-kit, PDGFRα, PDGFR****223'3f NEEDS TO BE ADDED TO TIMES NEW ROMAN GREEK FONT****, AKT, PT...
